Protocol No.: M17-380

A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children from 2 to Less than 12 Years of Age with Moderate to Severe Atopic Dermatitis (START UP)
Principal Investigator
Zinn, Zachary
Phase
III
Age Group
Children
Applicable Disease Site
Other
Participating Institutions
Health Sciences Center
West Virginia University
Contact
Erica Blystone, RN
Clinical Research Specialist
Phone: +1 304-293-3415

View on ClinicalTrials.gov